Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCLAIM-CX-072-002: CX-072 with or without ipilimumab in adults with solid tumors
NL-OMON49159Phase 2Active, not recruiting
- Sponsor
- CytomX Therapeutics, Inc.,
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pacmilimab and ipilimumab in Nonhematologic neoplasms (4 arms), sponsored by CytomX Therapeutics, Inc.,. Primary endpoints: Objective response rate and Pathologic response. Started Sep 2019; status: active, not recruiting.
02
Drugs
pacmilimabipilimumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON49159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49159.